

## U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 51

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Barnes-Jewish St. Peter's Hospital Department of Radiology 2. 10 Hospital Drive St. Peters, MO 63376	In accordance with letter dated <b>August 14, 2014,</b> 3. License number 24-18968-01 is amended in its entirety to read as follows: 4. Expiration date July 31, 2021 5. Docket No. 030-17414 Reference No.
--	---

6. Byproduct, source, and/or special nuclear material  A. Any byproduct material permitted by 10 CFR 35.100  B. Any byproduct material permitted by 10 CFR 35.200  C. Any byproduct material permitted by 10 CFR 35.300  D. Iodine-125 permitted by 10 CFR 35.400  E. Palladium-103 permitted by 10 CFR 35.400	7. Chemical and/or physical form  A. Any  B. Any  C. Any  D. Sealed sources (Medi-Physics, Inc., d/b/a GE Healthcare (formerly Oncura) Model 6711 (OncoSeed™) and IsoAID L.L.C. Model IAI-125A (Advantage™ I-125))  E. Sealed sources (Theragenics Corporation TheraSeed Model 200)	8. Maximum amount that licensee may possess at any one time under this license  A. As needed  B. As needed  C. One curie  D. Two curies  E. Two curies
--	---	--

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
  - B. Any imaging and localization study permitted by 10 CFR 35.200.
  - C. Any diagnostic or therapeutic study permitted by 10 CFR 35.300.
  - D. through E. Any manual brachytherapy study permitted by 10 CFR 35.400.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
24-18968-01

Docket or Reference Number  
030-17414

Amendment No. 51

CONDITIONS

10. A. Licensed material may be used at the licensee's facilities located at 10 Hospital Drive, St. Peters, Missouri.
- B. Licensed material listed in Subitem Nos. 6.D. through 6.E. may be used at the licensee's facilities located at 100 Entrance Way, St. Peters, Missouri.
- C. Licensed material listed in Subitem No. 6.C. limited to I-131, may be used at the licensee's facilities located at Siteman Cancer Center, 150 Entrance Way, St. Peters, Missouri.
11. Radiation Safety Officer: Constance Courtois, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14;
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Constance Courtois, M.D.

10 CFR 35.100, 35.200, and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).

Diana L. Westerfield, D.O.

10 CFR 35.200.

Martin B. Ast, M.D.

10 CFR 35.200.

Lannis Elese Hall-Daniels, M.D.

10 CFR 35.300 and 35.400.

Michael Penney, M.D.

10 CFR 35.100 and 35.200.

Meredith Byers, M.D.

10 CFR 35.100 and 35.200.

Joelle Biernacki, M.D.

10 CFR 35.100 and 35.200, and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).

Heather V. Garrett, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).

Hui Hua Shu, M.D.

10 CFR 35.100 and 35.200.

James Kelly, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
24-18968-01

Docket or Reference Number  
030-17414

Amendment No. 51

Authorized Users

Punita Gupta, M.D.

Robert Stachecki, M.D.

Ajay Chapa, M.D.

**Paula M. Leiva, M.D.**

Material and Use

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).


10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).

**10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).**

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated February 22, 2011; and
- B. Letter dated October 29, 2012.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date SEP 18 2014

By   
Sara A. Forster, M.S.  
Materials Licensing Branch  
Region III